Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection.
Adaptive immunity
Immunoglobulins
Immunology
Infectious disease
Malaria
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
18 06 2020
18 06 2020
Historique:
received:
13
02
2020
accepted:
06
05
2020
pubmed:
20
5
2020
medline:
9
6
2021
entrez:
20
5
2020
Statut:
epublish
Résumé
BACKGROUNDMalaria pathogenicity is determined, in part, by the adherence of Plasmodium falciparum-infected erythrocytes to the microvasculature mediated via specific interactions between P. falciparum erythrocyte membrane protein (PfEMP1) variant domains and host endothelial receptors. Naturally acquired antibodies against specific PfEMP1 variants can play an important role in clinical protection against malaria.METHODSWe evaluated IgG responses against a repertoire of PfEMP1 CIDR domain variants to determine the rate and order of variant-specific antibody acquisition and their association with protection against febrile malaria in a prospective cohort study conducted in an area of intense, seasonal malaria transmission.RESULTSUsing longitudinal data, we found that IgG antibodies against the pathogenic domain variants CIDRα1.7 and CIDRα1.8 were acquired the earliest. Furthermore, IgG antibodies against CIDRγ3 were associated with reduced prospective risk of febrile malaria and recurrent malaria episodes.CONCLUSIONThis study provides evidence that acquisition of IgG antibodies against PfEMP1 variants is ordered and demonstrates that antibodies against CIDRα1 domains are acquired the earliest in children residing in an area of intense, seasonal malaria transmission. Future studies will need to validate these findings in other transmission settings and determine the functional activity of these naturally acquired CIDR variant-specific antibodies.TRIAL REGISTRATIONClinicalTrials.gov NCT01322581.FUNDINGDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.
Identifiants
pubmed: 32427581
pii: 137262
doi: 10.1172/jci.insight.137262
pmc: PMC7406271
doi:
pii:
Substances chimiques
Antibodies, Protozoan
0
Immunoglobulin G
0
Protozoan Proteins
0
Banques de données
ClinicalTrials.gov
['NCT01322581']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : K08 AI125682
Pays : United States
Références
Cell. 1995 Jul 14;82(1):77-87
pubmed: 7541722
PLoS Negl Trop Dis. 2014 Sep 11;8(9):e3154
pubmed: 25210876
Cell. 1995 Jul 14;82(1):101-10
pubmed: 7606775
Mol Microbiol. 2003 Mar;47(5):1265-78
pubmed: 12603733
Cell Host Microbe. 2015 Jan 14;17(1):118-29
pubmed: 25482433
PLoS One. 2011 Mar 03;6(3):e14741
pubmed: 21390226
Nat Med. 1998 Mar;4(3):358-60
pubmed: 9500614
PLoS Pathog. 2012;8(4):e1002665
pubmed: 22532802
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12743-8
pubmed: 10535993
EMBO Mol Med. 2016 Aug 01;8(8):839-50
pubmed: 27354391
Parasite Immunol. 1994 Jul;16(7):361-70
pubmed: 7970875
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12045-12050
pubmed: 29078270
Clin Infect Dis. 2013 Jul;57(1):40-7
pubmed: 23487390
PLoS Pathog. 2010 May 20;6(5):e1000912
pubmed: 20502681
Infect Immun. 2018 Jul 23;86(8):
pubmed: 29784862
Eur J Immunol. 2017 Dec;47(12):2124-2136
pubmed: 28833064
PLoS Comput Biol. 2010 Sep 16;6(9):
pubmed: 20862303
PLoS Pathog. 2005 Nov;1(3):e26
pubmed: 16304608
J Infect Dis. 2019 Feb 15;219(5):808-818
pubmed: 30365003
Elife. 2018 Jun 26;7:
pubmed: 29943728
EMBO Mol Med. 2019 Feb;11(2):
pubmed: 30610112
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17471-6
pubmed: 17959777
Infect Immun. 2015 Aug;83(8):3096-103
pubmed: 26015475
Nature. 1997 Jul 17;388(6639):292-5
pubmed: 9230440
Malar J. 2016 May 05;15(1):258
pubmed: 27149991
Nature. 1998 Jul 23;394(6691):392-5
pubmed: 9690477
Nat Med. 1999 Mar;5(3):340-3
pubmed: 10086393
Sci Signal. 2009 May 26;2(72):re3
pubmed: 19471024
Science. 1996 Jun 7;272(5267):1502-4
pubmed: 8633247
Immunol Rev. 2020 Jan;293(1):230-252
pubmed: 31562653
Malar J. 2008 Jun 12;7:108
pubmed: 18549480
Nature. 2002 Oct 3;419(6906):498-511
pubmed: 12368864
Infect Immun. 2017 Mar 23;85(4):
pubmed: 28138022
Cell Host Microbe. 2017 Mar 8;21(3):403-414
pubmed: 28279348
Infect Immun. 2018 Oct 25;86(11):
pubmed: 30150256
Lancet. 1990 Dec 15;336(8729):1457-60
pubmed: 1979090
Nat Rev Microbiol. 2017 Aug;15(8):479-491
pubmed: 28603279
Protein Expr Purif. 2006 Nov;50(1):58-67
pubmed: 16884920
Nat Commun. 2016 Sep 26;7:12837
pubmed: 27667267
Am J Trop Med Hyg. 2009 Dec;81(6):987-93
pubmed: 19996426
J Clin Invest. 2012 Sep;122(9):3227-38
pubmed: 22850879
Infect Immun. 1999 Feb;67(2):733-9
pubmed: 9916084
Infect Immun. 1991 Jun;59(6):2135-9
pubmed: 2037374
Cell Microbiol. 2013 Dec;15(12):1976-83
pubmed: 23957661
Infect Immun. 2010 Nov;78(11):4653-9
pubmed: 20823214
BMC Med. 2017 Oct 13;15(1):183
pubmed: 29025399
Cell Host Microbe. 2017 Nov 8;22(5):601-614.e5
pubmed: 29107642
Cell Host Microbe. 2019 Nov 13;26(5):579-590.e5
pubmed: 31726028
Malar J. 2003 Sep 10;2:27
pubmed: 14565852
Trends Parasitol. 2014 Sep;30(9):436-44
pubmed: 25113859
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3270-9
pubmed: 27185931
J Biol Chem. 2009 Sep 25;284(39):26951-63
pubmed: 19633296
Vaccine. 2004 Jul 29;22(21-22):2701-12
pubmed: 15246600
Bioinformatics. 2013 Oct 15;29(20):2653-4
pubmed: 23926226
J Immunol. 2009 Sep 1;183(5):3356-63
pubmed: 19675168
PLoS One. 2012;7(10):e46094
pubmed: 23056238
Nature. 2013 Jun 27;498(7455):502-5
pubmed: 23739325
Wellcome Open Res. 2019 Dec 3;4:193
pubmed: 32055709
Cell. 1995 Jul 14;82(1):89-100
pubmed: 7606788
J Infect Dis. 2014 Mar 1;209(5):789-98
pubmed: 24133188